A trastuzumab-modified, mannosylated liposome system loaded with gefitinib (kinase inhibitor) and vorinostat (histone deacetylase inhibitor) was used in a nonsmall cell lung cancer (NSCLC) mouse model for dual-targeting of both TAM and HER2-positive lung cancer cells [185]. Here, ERBB2 is linked to lung cancer.